Migraine is prevalent condition that can be debilitating. Previous research has indicated that people with migraine perform worse on measures of cognitive function, even when they are not currently experiencing an attack. This is problematic because poor cognitive function is associated with a host of negative outcomes, including increased risk of car crash, reduced capacity to relate to others, impaired mood, and lower life satisfaction. Calcitonin gene-related peptide (CGRP) antagonist drugs represent an effective treatment for migraine symptoms such as pain. Here the focus is on a specific CGRP antagonist drug, Rimegepant. It is possible that when taken as a preventative, Rimegepant mitigates the impairment in cognitive function typically seen in people with migraine and improves mood. Therefore, the goal of this project is to assess the impact of Rimegepant on two novel outcomes for people with migraine: cognitive function and mood. 

This project is funded by Pfizer.